IMMUNOMODULATORY AGENTS AND PROTEASOME INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA

被引：9

作者：

Noonan, Kimberly ^{[1
]}

Colson, Kathleen ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA

来源：

SEMINARS IN ONCOLOGY NURSING | 2017年 / 33卷 / 03期

关键词：

multiple myeloma; immunomodulatory drugs; proteasome inhibitors; treatment; side effects; LENALIDOMIDE PLUS DEXAMETHASONE; STEM-CELL TRANSPLANTATION; LOW-DOSE DEXAMETHASONE; NEWLY-DIAGNOSED MYELOMA; LONG-TERM SURVIVAL; ELDERLY-PATIENTS; OPEN-LABEL; CONSENSUS STATEMENT; ANTITUMOR-ACTIVITY; ORAL MELPHALAN;

D O I：

10.1016/j.soncn.2017.05.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OBJECTIVE: To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). DATA SOURCES: Journal articles, research reports, state of the science papers, and clinical guidelines. CONCLUSION: There has been a tremendous increase of new agents to treat multiple myeloma in the last 15 years. The IMiDs and PIs remain essential components of many anti-myeloma regimens. IMPLICATIONS FOR NURSING PRACTICE: With these advances in the therapeutic landscape, knowledge of these drugs, side effects and nursing implications are essential to improve outcomes. Patient education is also of vital importance in achieving optimal responses to treatment.

引用

下载

页码：279 / 291

页数：13

共 50 条

[21] Novel proteasome inhibitors in multiple myeloma
不详
CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (05): : 370 - 372
[22] PROTEASOME INHIBITORS FOR USE IN MULTIPLE MYELOMA
Jain, S.
Satija, N.
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2014, 5 (02): : 320 - 329
[23] Busulfan and cyclophosphamide as a conditioning regimen for autologous transplantation in patients with multiple myeloma after treatment with proteasome inhibitors and/or immunomodulatory drugs
Kang, Ka-Won
Jeon, Min Ji
Yu, Eun Sang
Kim, Dae Sik
Choi, Chul Won
Lee, Byung-Hyun
Lee, Se Ryeon
Sung, Hwa Jung
Park, Yong
Kim, Byung Soo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S41 - S41
[24] The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Paul, Barry
Loitsch, Gavin
Feinberg, Daniel
Barak, Ian
Li, Zhiguo
Wang, Endi
Zhao, Yue
Dupuis, Megan
Kang, Yubin
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[25] Kinase inhibitors as potential agents in the treatment of multiple myeloma
Abramson, Hanley N.
ONCOTARGET, 2016, 7 (49) : 81926 - 81968
[26] Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma
Fradley, Michael G.
Groarke, John D.
Laubach, Jacob
Alsina, Melissa
Lenihan, Daniel J.
Cornell, Robert F.
Maglio, Michelle
Shain, Kenneth H.
Richardson, Paul G.
Moslehi, Javid
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (02) : 271 - 275
[27] Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma
Bringhen, Sara
Gay, Francesca
Donato, Francesca
Troia, Rossella
Mina, Roberto
Palumbo, Antonio
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (09) : 1193 - 1209
[28] Mechanism of action of immunomodulatory agents in multiple myeloma
Thomas Reske
Mariateresa Fulciniti
Nikhil C. Munshi
Medical Oncology, 2010, 27 : 7 - 13
[29] Mechanism of action of immunomodulatory agents in multiple myeloma
Reske, Thomas
Fulciniti, Mariateresa
Munshi, Nikhil C.
MEDICAL ONCOLOGY, 2010, 27 : 7 - 13
[30] Allogeneic haematopoietic cell transplantation for relapsed or progressive multiple myeloma in the era of immunomodulatory drugs and proteasome inhibitors
Schneidawind, D.
Oehrlein, K.
Weisel, K.
Faul, C.
Kanz, L.
Bethge, W. A.
BONE MARROW TRANSPLANTATION, 2013, 48 : S208 - S208

← 1 2 3 4 5 →